Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

Cardiologists are first in world to use new TAVR catheter from Boston Scientific
The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.
Shockwave Medical launches new IVL catheter for targeting challenging lesions in PAD patients
The new-look Javelin Peripheral IVL Catheter was designed to travel through extremely narrowed blood vessels and target plaques with up to 120 pulses.
Teleflex to acquire Biotronik’s vascular intervention business for $791M, split into 2 separate entities
The acquisition helps Teleflex expand its interventional and vascular portfolios. Biotronik, meanwhile, is shifting its focus toward implantable devices and digital healthcare.
Know your options: What cardiologists recommend when alternative access is required for TAVR
Transfemoral TAVR is not always a viable option. In those instances, the two most effective alternatives are transcarotid access and transcaval access, according to a new SCAI expert consensus statement.
Cardiovascular societies support Medicare coverage for renal denervation
CMS is expected to release a proposed national coverage determination decision memo by July.

Tracking TAVR’s impact on gastrointestinal bleeding symptoms

TAVR patients with gastrointestinal bleeding (GIB) were linked to longer lengths of stay and a higher risk of acute kidney injury than patients without GIB.

Two examples of new left atrial appendage occluders (LAAO), the Conformal omn left and the Laminar on the right. evi Nair, MD, FACC, FHRS, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit. #TVT #TVT2020 #LAA #LAAO #EPeeps

VIDEO: Advances in left atrial appendage occlusion technology

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

Cardiologists push back on FDA’s thyroid monitoring/contrast media proposal

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties.

The Boston Scientific Acurate neo2,. Abbott Portico and the new Edwards Sapien X4 TAVR valves were hot topics of discussion at TCT 2022. #TVT #TVT22 #TVT2022

VIDEO: TAVR's long-term impact on patient care

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care.

Links to all the late-breaking structural heart studies at TVT 2022

Here are links to more information for all the late-breaking presentations at the 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

VIDEO: How to build a structural heart program

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program.

What peridevice leaks after LAAO mean for patient health

The study's authors reviewed data from more than 50,000 patients, presenting their findings in JACC: Clinical Electrophysiology.

Resheathing heart valves during TAVR does not increase risk of complications

Researchers tracked both short- and long-term outcomes, sharing their findings in the Journal of the American Heart Association.

Cath Lab

Cardiologists are first in world to use new TAVR catheter from Boston Scientific

Shockwave Medical launches new IVL catheter for targeting challenging lesions in PAD patients

Teleflex to acquire Biotronik’s vascular intervention business for $791M, split into 2 separate entities

Know your options: What cardiologists recommend when alternative access is required for TAVR

Cardiovascular societies support Medicare coverage for renal denervation